CAMBRIDGE, Mass., Sept. 18,
2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced the
closing of its previously announced upsized underwritten public
offering of 5,750,000 shares of Class A common stock, which
includes 750,000 shares of Class A common stock sold pursuant to
the exercise in full by the underwriters of their option to
purchase additional shares, at a price to the public of
$100.00 per share. The gross proceeds
of the offering were approximately $575.0
million, before deducting underwriting discounts and
commissions and other offering expenses. All shares in the offering
were offered by Nuvalent.
J.P. Morgan, TD Cowen, Jefferies and Stifel are acting as joint
book-running managers for the offering.
The shares were offered by Nuvalent pursuant to an automatically
effective shelf registration statement that was filed with the
Securities and Exchange Commission ("SEC") on March 16, 2023. This offering was made only by
means of a prospectus and prospectus supplement that form a part of
the registration statement. A final prospectus supplement relating
to and describing the terms of the offering has been filed with the
SEC and may be obtained for free by visiting the SEC's website at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus can be obtained from: J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717,
or by email at prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855)
495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com;
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY
10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com or Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone
at 415-364-2720 or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Nuvalent
Nuvalent, Inc.
(Nasdaq: NUVL) is a clinical-stage
biopharmaceutical company focused on creating precisely targeted
therapies for patients with cancer, designed to overcome the
limitations of existing therapies for clinically proven
kinase targets. Leveraging deep expertise in chemistry and
structure-based drug design, we develop innovative small molecules
that have the potential to overcome resistance, minimize adverse
events, address brain metastases, and drive more durable
responses. Nuvalent is advancing a robust pipeline
with investigational candidates for ROS1-positive,
ALK-positive, and HER2-altered non-small cell lung cancer,
and multiple discovery-stage research programs.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-announces-closing-of-upsized-public-offering-of-common-stock-302252236.html
SOURCE Nuvalent, Inc.
